by David Wallace September 1, 2026 Update Big news for the ET community: The FDA has approved BESREMi® for adults with essential thrombocythemia (ET). Stay tuned for our detailed article explaining what this approval could mean for patients. Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide […]
Interferon Treatment for MPNs: What You Need to Know
by David Wallace The Big Picture If you’ve been diagnosed with a myeloproliferative neoplasm (MPN) such as polycythemia vera, essential thrombocythemia, or myelofibrosis, you’ve likely heard about interferon therapy. Keep reading to discover what current research tells us about this treatment option. What Exactly Is Interferon? Think of interferon as your body’s natural antiviral security […]
Breakthrough CALR Therapy Shows High Response Rate in ET
by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]
New Scoring Model Improves Prediction of Outcomes in Essential Thrombocythemia
by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
